Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging

Launched by SHANGHAI MENTAL HEALTH CENTER · Oct 11, 2016

Keywords

ClinConnect Summary

This clinical trial is looking at how to diagnose and treat Alzheimer's disease early, specifically in people with Mild Cognitive Impairment (MCI). The researchers will use a special imaging technique called Flutemetamol-PET to see if there are signs of senile plaques in the brain, which are linked to Alzheimer's. They will also explore new blood tests and brain scans that could help identify MCI related to Alzheimer's. Additionally, the trial will test the safety and effectiveness of a treatment called Huperzine A over a year.

To participate in this study, individuals need to have memory complaints, which should ideally be confirmed by a family member. They should also show some objective memory issues but still have normal overall thinking abilities and be able to carry out daily activities independently. Importantly, they should not have dementia or other types of dementia besides Alzheimer's. The trial is not yet recruiting participants, but it aims to gather more insight into early diagnosis and treatment options for those at risk of developing Alzheimer's disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • memory complaint, preferably corroborated by a spouse or relative.
• • objective memory impairment.
• • normal general cognitive function.
• • intact activities of daily living.
• • absence of dementia.
• • the positive of brain senile plaque.
• Exclusion Criteria:
• • more than two lacuna ischemia (of diameter \< 1 cm) as revealed by MRI fluid-attenuated inversion recovery (FLAIR) sequence.
• • other type of dementia except AD